Evidence map›Paper›PMID 27511856›Full record

Trial reportInternational journal of radiation oncology, biology, physics2016

Image Guided Planning for Prostate Carcinomas With Incorporation of Anti-3-[18F]FACBC (Fluciclovine) Positron Emission Tomography: Workflow and Initial Findings From a Randomized Trial.

Eduard Schreibmann, David M Schuster, Peter J Rossi, Joseph Shelton, Sherrie Cooper, Ashesh B Jani

Erratum issued Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of radiation oncology, biology, physics, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT03373006 (A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer), which is not on this map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03373006 phase2completednot on this mapstarted 2018, after this paper: background citation

A Phase II Study to Evaluate Axumin PET/CT for Risk Stratification for Laser Focal Therapy of Intermediate Risk Localized Prostate Cancer

TypeinterventionalSponsorHALO DiagnosticsRan2018 to 2020Enrolled20ConditionsProstate CancerArmsAxumin PET/CT
3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Lancet (London, England) · 2021
    Trial
  2. Trial
  3. Lesion segmentation onFrontiers in oncology · 2023
    Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Update onJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2018
    Review
  9. Review
  10. Article
  11. Feasibility of Dose Escalating [Advances in radiation oncology
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors.

Eduard SchreibmannDepartment of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia. Electronic address: eschre2@emory.edu.
David M SchusterDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Peter J RossiDepartment of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.
Joseph SheltonDepartment of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.
Sherrie CooperDepartment of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.
Ashesh B JaniDepartment of Radiation Oncology and Winship Cancer Institute of Emory University, Emory University, Atlanta, Georgia.

Funding

Molecular Imaging with FACBC PET-CT to Improve Post prostatectomy RadiotherapyR01CA169188 · NCI · EMORY UNIVERSITY · PI JANI, ASHESH, SCHUSTER, DAVID MICHAEL · 2012 to 2016
$2.1M
NCI NIH HHS R01 CA169188
6 · The paper itself

Abstract

purpose(18)F-Fluciclovine (anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid) is a novel positron emission tomography (PET)/computed tomography (CT) radiotracer that has demonstrated utility for detection of prostate cancer. Our goal is to report the initial results from a randomized controlled trial of the integration of (18)F-fluciclovine PET-CT into treatment planning for defining prostate bed and lymph node target volumes. METHODS AND MATERIALS: We report our initial findings from a cohort of 41 patients, of the first enrolled on a randomized controlled trial, who were randomized to the (18)F-fluciclovine arm. All patients underwent (18)F-fluciclovine PET-CT for the detection of metabolic abnormalities and high-resolution CT for treatment planning. The 2 datasets were registered first by use of a rigid registration. If soft tissue displacement was observable, the rigid registration was improved with a deformable registration. Each (18)F-fluciclovine abnormality was segmented as a percentage of the maximum standard uptake value (SUV) within a small region of interest around the lesion. The percentage best describing the SUV falloff was integrated in planning by expanding standard target volumes with the PET abnormality.

resultsIn 21 of 55 abnormalities, a deformable registration was needed to map the (18)F-fluciclovine activity into the simulation CT. The most selected percentage was 50% of maximum SUV, although values ranging from 15% to 70% were used for specific patients, illustrating the need for a per-patient selection of a threshold SUV value. The inclusion of (18)F-fluciclovine changed the planning volumes for 46 abnormalities (83%) of the total 55, with 28 (51%) located in the lymph nodes, 11 (20%) in the prostate bed, 10 (18%) in the prostate, and 6 (11%) in the seminal vesicles. Only 9 PET abnormalities were fully contained in the standard target volumes based on the CT-based segmentations and did not necessitate expansion.

conclusionsThe use of (18)F-fluciclovine in postprostatectomy radiation therapy planning was feasible and led to augmentation of the target volumes in the majority (30 of 41) of the patients studied.

Indexed as

Carboxylic AcidsCyclobutanesHumansMaleMiddle AgedPilot ProjectsPositron Emission Tomography Computed TomographyProstatic NeoplasmsRadiopharmaceuticalsRadiotherapy DosageRadiotherapy, Image-GuidedRadiotherapy Planning, Computer-AssistedReproducibility of ResultsSensitivity and SpecificityTreatment OutcomeWorkflowCarboxylic AcidsCyclobutanesfluciclovine F-18Radiopharmaceuticals

Identifiers

PMID27511856
PMCPMC5645084

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.